



EXPRESS SCRIPTS®

**Express Scripts, Inc.
Pharmacy and Therapeutics Committee
Proceedings
January 22, 2009**

New Drug Evaluations

The Committee reviewed the following new drugs.

- A. Banzel™ (rufinamide tablets) – Eisai**
- B. Mozobil™ (plerixafor injection) – Genzyme**
- C. Rapaflo™ (silodosin capsules) – Watson**

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. Boniva® (ibandronate sodium tablets - 150 mg) Roche** - New indication for the 150 mg tablet: Prevention of osteoporosis in postmenopausal women.
- B. Boostrix® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) GlaxoSmithKline)** – Expanded age range, now indicated for patients aged 10 to 64 years old (previously was 10 to 18 years old). Labeled indication is now: Indicated for active booster immunization against tetanus, diphtheria, and pertussis as a single dose in individuals 10 years through 64 years of age.
- C. PegIntron® (peginterferon alfa-2b injection, powder for solution for subcutaneous use) Schering Corporation** – Expanded age range, now indicated for combination use with ribavirin (Rebetol®) in patients aged 3 years and older (previously was 18 years and older). Labeled indication is now: PegIntron in combination with Rebetol (ribavirin) is indicated for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease previously untreated with interferon alpha.
- D. Prezista® (darunavir tablets) Tibotec** – Expanded indication to include pediatric patients aged 6 years of age and older for co-administration with ritonavir, and with other antiretroviral agents, for the treatment of human immunodeficiency virus (HIV)-1 infection.
- E. Gleevec® (imatinib mesylate tablets) Novartis** – Adjuvant treatment of adult patients following resection of Kit (CD117) positive gastrointestinal stromal tumors.
- F. Reclast® (zoledronic acid injection) Novartis** – Treatment to increase bone mass in men with osteoporosis.

New Clinical Line Extensions

The Committee reviewed one new clinical line extension.

- A. Apriso™ (mesalamine extended-release capsules) Salix Pharmaceutical)**
- B. Astepro™ (azelastine hydrochloride nasal spray) MEDA Pharmaceuticals**
- C. Epiduo™ (adapalene 0.1% and benzoyl peroxide 2.5% gel) Galderma**